Form 4: ZyVersa Therapeutics Director Gregory Freitag Granted Stock Options

ZyVersa Therapeutics, Inc. Director Gregory Gene Freitag was granted 11,066 stock options with an exercise price of $0.59, vesting over three years.

Summary

• Gregory Gene Freitag, a Director of ZyVersa Therapeutics, Inc. (ZVSA), was granted 11,066 stock options.
• The options have an exercise price of $0.59 per share.
• The grant date for these options is July 11, 2025.
• The options will vest and become exercisable in equal annual installments on the first three anniversaries of the grant date.
• The expiration date for these options is July 11, 2035.
• Vesting is subject to Mr. Freitag's continued service on each vesting date.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive sign of alignment between management and shareholder interests, encouraging long-term commitment. It's a standard compensation practice.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from the director.

Negatives

• No immediate negative financial implications are apparent from this filing, as it reports an equity grant.

Risks

• The value of the stock options is subject to the future performance of ZyVersa Therapeutics, Inc.'s common stock.
• If the stock price does not exceed the exercise price of $0.59, the options may expire worthless.
• Vesting is subject to continued service, meaning the options could be forfeited if the director's service ceases before full vesting.

Future Outlook

The grant of stock options with a future vesting schedule indicates an expectation of continued service from the director and aligns their incentives with the company's long-term performance.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, aiming to align leadership interests with shareholder value and incentivize long-term commitment, especially for companies like ZyVersa Therapeutics (ZVSA) which are likely in development stages.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a common practice across publicly traded companies, particularly in the biotech sector, to incentivize long-term performance and retention.
• The exercise price of $0.59 is tied to the stock price at the time of grant, which is typical for incentive stock options.
• A three-year vesting schedule is a standard duration for equity grants to executives and directors, balancing immediate incentive with long-term commitment.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by incentivizing an increase in stock value.

Next Steps

• Continued service of Gregory Gene Freitag as a Director of ZyVersa Therapeutics, Inc.
• Vesting of the granted stock options in equal annual installments on the first three anniversaries of July 11, 2025.
• Potential exercise of options by Gregory Gene Freitag upon vesting and if the stock price is favorable.

Key Dates

Keywords

ZyVersa Therapeutics, ZVSA, Stock Options, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Gregory Freitag